1 / 15

Clinical Bioinformatics: the need for CBAS and SCBC in Applied Sciences?

Clinical Bioinformatics: the need for CBAS and SCBC in Applied Sciences?. Dr James Mah MBBS(Lon), BSc(Hons,Lon). Chair, CBAS 2009 Singapore Email: tutorsgsg@yahoo.com.sg. Clinical Bioinformatics. The use of informatics tools and techniques to study and analyse biomedical and genetic data

ehuckstep
Download Presentation

Clinical Bioinformatics: the need for CBAS and SCBC in Applied Sciences?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Bioinformatics: the need for CBAS and SCBC in Applied Sciences? Dr James Mah MBBS(Lon), BSc(Hons,Lon). Chair, CBAS 2009 Singapore Email: tutorsgsg@yahoo.com.sg

  2. Clinical Bioinformatics • The use of informatics tools and techniques to study and analyse biomedical and genetic data • Involves the development of new tools and algorithms to solve biomedical issues • Involves new discovery of biomedical knowledge and know how • Covers and overlaps with many disciplines and fields in applied sciences Clinical/biomedical example……..

  3. CLINICAL BIOINFORMATICS • New methods to rapidly and conveniently screen any genetic variant -probability of association with disease risk -probability of treatment outcome

  4. The Clinical Bioinformatics Cycle Egs Clinical Bioinformatics (NEW!) Results? DISEASE Cure HEALTH Prevention CANCER RISK PREDICTION DRUG (outcome) DEATH Personalised Medicine (Survival outcome) TREATMENT OUTCOMES eg TOXICITY

  5. CASE STUDY 1 –DRUG TREATMENT OUTCOME MODEL Gene VKORC1(Vitamin K epoxide reductase complex 1) story a)Study in European-American population (Rieder et al 2005)

  6. b)Study in Asian population (Lee SC et al 2006)

  7. CASE STUDY 2 –SURVIVAL OUTCOMEMODEL THE GEMCITABINE NON-SMALL CELL LUNG CANCER STORY

  8. POTENTIAL USES OF NEW BIOMEDICAL IMAGING TOOLS • Screening For suspicious lesions -population screening Eg for breast cancer detection -epidemiological studies -risk stratification – cancer prevention, treatment programmes

  9. 1st Clinical Bioinformatics Symposium on Applied Sciences (CBAS) 2009 • Promote awareness of Clinical Bioinformatics and its applications in biomedical sciences and healthcare • Sharing of views by renowned speakers invited to tackle complex and diverse topics in Clinical Bioinformatics • Networking session and SCBC to allow participants to showcase their work to foster inter-disciplinary collaborations • Help foster the Clinical Bioinformatics Cycle

  10. The Singapore Clinical Bioinformatics Consortium (SCBC) • Part of CBAS to continue inertia and initiative • Seek representatives from each institution to strengthen ties and build up strong links for collaboration in the field of Clinical Bioinformatics • Potential aims would be to initiate key or core project areas with potential for development both locally as well as regionally

  11. The Singapore Clinical Bioinformatics Consortium (SCBC) • Tie-ups with industry and pharmaceutical companies are also encouraged • Invitation to be part of this exciting Consortium as committee members to spearhead and drive new clinical bioinformatics projects both regionally and internationally

  12. The Singapore Clinical Bioinformatics Consortium (SCBC) • Invitation for contribution in but not limited to: -Biomedical Imaging -Translational Research Eg Bench-to-bedside or personalized medicine -Genomics Eg functional annotation of genetic variants with respect to complex/clinical diseases -Drug discovery Eg novel drug target identification and discovery

  13. Acknowledgements • Dr Victor Tong and InCoB 2009 committee • A*STAR • All our sponsors and dedicated supporters • Distinguished speakers • Dedicated CBAS 2009 organising committee: Tze Hau, Meng Ling, Luke, Winnie, all volunteers • Delegates and attendees • All those indirectly or directly made this event possible

More Related